Likewise, further data suggest a potential role of biological treatments used in maintenance and remission periods, such as TNF-α inhibitors, as a protective factor against nonalcoholic fatty liver disease in patients with IBD (22, 23). The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.